Although fatigue is common after allogeneic hematopoietic cell transplantation, little is known about fatigue in patients with chronic GvHD (cGvHD). The aim of this study was to explore factors associated with fatigue in cGvHD. Data were drawn from a sequentially recruited, cross-sectional study of adults with moderate or severe cGvHD (n = 263). Respondents were classified as fatigued or not fatigued based on their response to a single item regarding loss of energy from the Lee cGvHD Symptom Scale. In univariate analysis, factors significantly associated with fatigue included performance status, number of prior cGvHD therapies, cGvHD symptom bother, self-assessed physical and mental health, nutritional status, walk velocity and self-reported physical activity. There were no significant associations between fatigue and disease-related cGvHD variables. Multivariable logistic regression demonstrated that being less active and having pulmonary and/or muscle/joint symptoms were independently associated with fatigue. In conclusion, clinically significant fatigue was prevalent in more than one-third of subjects with cGvHD, and was disabling. Absence of association with measures of cGvHD severity underscores the need to elucidate the pathogenesis of fatigue and its relationship with inflammatory activity. Pulmonary and muscle/joint symptoms and physical inactivity represent potential targets for intervention in clinical studies.
INTRODUCTION
Chronic GvHD (cGvHD) is a late complication after allogeneic hematopoietic cell transplantation (HCT) affecting 30-80% of transplant survivors, and is a leading cause of morbidity and nonrelapse mortality. [1] [2] [3] [4] Chronic GvHD is characterized by alloand autoimmune dysregulation, and can affect multiple organs including the skin, eyes, mouth, gastrointestinal tract, liver, lungs, joints and genitourinary tract. 5, 6 Chronic GvHD is also associated with a graft-versus-tumor effect and a lower rate of malignant relapse. 7, 8 Organ complications secondary to cGvHD and immunosuppressive medications contribute to the substantial impact on morbidity.
Fatigue is a prevalent and distressing symptom in patients treated for hematologic malignancy including those who have undergone HCT, and negatively affects quality of life. [9] [10] [11] [12] [13] The prevalence of fatigue in HCT has been estimated to range from 56 to 65%, and one-third of fatigued patients rate their fatigue as severe or distressing. [14] [15] [16] Moderate to severe fatigue can persist for years after HCT, and its etiology is likely multifactorial. [17] [18] [19] Although fatigue in patients with cGvHD has not been well characterized, cGvHD itself has a significant negative impact on quality of life and function, and symptom burden is an important component of these adverse outcomes. [20] [21] [22] [23] [24] [25] Although studies indicate that patients with cGvHD report more fatigue compared with those without cGvHD, the factors associated with fatigue in this patient population have not been studied. 15, 26, 27 The etiology of fatigue in cancer survivors likely involves the interaction of several mechanisms, and a number of explanatory models of the psychophysiology of fatigue have been proposed. 28 Risk factors for fatigue following cancer treatment can include anemia, comorbidities, concurrent symptoms, impaired sleep quality, mood disturbance, cachexia, sarcopenia, deconditioning and treatment with medications with sedating side effects. 29 Evidence also links fatigue with gene polymorphisms, circadian rhythm disruption, immune dysregulation, abnormal cortisol secretion and/or proinflammatory cytokine activity. 30, 31 Other models emphasize imbalanced energy intake, metabolism and expenditure, 32, 33 or propose dysregulation in the function of immune-neuroendocrine-based regulatory systems. [34] [35] [36] The aim of this analysis is to examine the prevalence and correlates of fatigue as defined by a single item on a patient-reported symptom scale in long-term survivors of HCT affected with moderate to severe cGvHD.
(clinicaltrials.gov identifier: NCT00092235). A total of 280 adult patients underwent informed consent and were enrolled between 2004 and 2013, and participated in a comprehensive evaluation by a multidisciplinary team. Assessments were performed by specialists in dermatology, ophthalmology, dentistry, rehabilitation medicine, gynecology, pain and palliative care and HCT with specific expertise in cGvHD. Eleven patients were determined to have an inconclusive diagnosis of cGvHD, and were excluded from the analysis. Six patients were excluded because of incomplete data. In all, 263 patients with cGvHD were included in the cohort for this analysis.
Measures
Demographic, clinical and transplant characteristics. Demographic and clinical characteristics were obtained at the time of study visit. Transplant characteristics including underlying disease, conditioning regimen, donor source and stem cell source were gathered from participants' medical records and a comprehensive history and physical.
Clinician-reported cGvHD characteristics. Chronic GvHD severity was assessed based on the National Institutes of Health (NIH) global severity score and the organ-specific score; 37 the mean of the organ-specific severity scores, number of organs involved and number of prior cGvHD therapies received were tabulated. Chronic GvHD onset (progressive, quiescent or de novo), cGvHD classification (classic, overlap and late acute) and time from transplant and time from cGvHD onset to enrollment on study were determined. Intensity of immunosuppression was classified on a 4-point scale. 20 Chronic GvHD was categorized as active or not active, based on the clinician's therapeutic intent at the time of visit. 38 Pulmonary manifestations were captured by FEV-1 (forced expiratory volume in 1 second) and lung function score (based on FEV-1 and DLCO (diffusing capacity for carbon monoxide) adjusted for hemoglobin). The percentage of body surface area involved with cutaneous erythema, sclerosis and any involvement was documented by a dermatologist with expertise in cGvHD.
Functional capacity
Functional capacity was assessed by a physiotherapist's measurement of range of motion, grip strength and the 2 min walk velocity. Subjects were assigned a score for each of these tests based on the percentage reduction from the normal range of values (normal = 0-25% reduction, mild = 26-50% reduction, moderate = 51-75% reduction and severe = 475% reduction).
Nutritional status
Nutritional status was determined using the nutrition global assessment from the patient-generated subjective global assessment. 39 Body mass index o21 kg/m 2 was considered to reflect malnutrition and adverse body composition. 40 In addition, serum albumin and prealbumin levels were collected.
Patient-reported outcomes
Chronic GvHD symptom bother was evaluated using the Lee cGvHD Symptom Scale (LSS). 41 This instrument assesses the degree to which respondents have been bothered in the past month by 30 common cGvHD symptoms. As detailed below, the response to a single item from the LSS asking about 'loss of energy' was used to classify a respondent as having clinically significant fatigue. Respondents indicated the extent to which they were bothered by loss of energy using a 5-point scale, with 0 being 'not at all', 1 being 'slightly', 2 being 'moderately', 3 being 'quite a bit' and 4 being 'extremely'. Given the high prevalence of fatigue in HCT survivors, we were specifically interested in determining factors associated with clinically significant fatigue. Thus, those respondents who indicated that they were not at all, slightly or moderately bothered by loss of energy were classified as 'not fatigued', whereas those who answered that they were quite a bit or extremely bothered by loss of energy were classified as 'fatigued'. To examine the association between fatigue and cGvHD symptom bother, a modified LSS total score was calculated using all items except the 'loss of energy' item. This modified LSS score was used in the univariate and multivariable analyses.
Physical status and mental health status were evaluated using the Medical Outcomes Study Short Form-36 (SF-36) (version 2). 42, 43 In addition, the vitality subscale of the SF-36 was employed to support the concurrent validity of the fatigue classification. The use of norm-based scoring algorithms facilitates the interpretation of SF-36 scores such that any score below 50 is below the average range for the US population. 44 Self-reported physical activity was evaluated as a correlate of fatigue using the maximum activity score (MAS) and adjusted activity score (AAS) derived from the Human Activity Profile (HAP), a 94-item self-report measure that provides valid and reliable estimates of physical activity in persons with a range of chronic conditions. 45 
Laboratory data
Laboratory data from analyses performed in a CLIA (Clinical Laboratory Improvement Amendments)-certified lab at the NIH were obtained at the time of the study visit. Laboratory parameters included those reflecting cGvHD disease severity (platelets), inflammatory activity (erythrocyte sedimentation rate, C-reactive protein, C3, C4, ferritin) and other comorbid conditions that could contribute to fatigue, including anemia (hemoglobin) and thyroid dysfunction (thyroid-stimulating hormone).
Statistical analysis
Nonparametric tests were used to compare variables of interest between patients with and without fatigue. Continuous variables were compared using a Wilcoxon rank sum test, and ordered categorical parameters were compared using the Cochran-Armitage test for trend. Dichotomous parameters were compared using Fisher's exact test. Unordered categorical variables were compared using Mehta's modification to Fisher's exact test. Variables found to be significantly associated with fatigue in univariate analysis were included in the multivariable logistic regression analysis to identify the set of factors that jointly predict fatigue. Additional variables were included that may function as confounders or covariates. Odds ratios and 95% confidence intervals are reported for continuous and categorical variables. Only P-values of o0.005 were considered statistically significant, whereas 0.005 ⩽ P o0.05 represented strong trends.
RESULTS

Patient characteristics
All 263 participants included in this analysis met the diagnostic criteria for cGvHD according to NIH Consensus Criteria. 37 Median age was 48.0 years (range 18-69), and approximately half (45%) were female. More than two-thirds had severe cGvHD by NIH consensus criteria (70.7%), and were a median of 35 months (range 4.1-293.0) post transplant. Participants had received a median of four (range 0-9) prior therapies for cGvHD, and had five (range 1-8) organ systems involved with cGvHD (Supplementary Table 1 ).
Prevalence of fatigue Overall, 84% of respondents endorsed any fatigue, with 39% of respondents indicating that they were bothered 'quite a bit' or 'extremely' by loss of energy (16% were bothered 'not at all', 22% 'slightly', 23% 'moderately', 27% 'quite a bit' and 12% 'extremely') (Supplementary Table 1) .
To support the concurrent validity of the fatigue classification, SF-36 vitality subscale scores were compared. Lower vitality scores reflect greater fatigue, and scores of ⩽ 40 may be considered to represent severe fatigue. [46] [47] [48] Patients who were classified as fatigued based on their response to the single item from the Lee Scale had a mean vitality score of 37.8 (s.d. ± 1.14), whereas those who were classified as not fatigued had a mean vitality score of 48.9 (s.d. ± 0.78). This difference is both statistically significant (P o 0.0001) and exceeds the minimally clinically important difference of 5 points (Table 1 and Figure 1 ). 49 Correlates of fatigue In the univariate analysis, several parameters were significantly associated (P o 0.005) or demonstrated a strong trend toward an association (0.005 ⩽ P o 0.05) with fatigue (Table 1) . Few clinical, transplant or cGvHD disease characteristics were associated with fatigue. There was a trend toward a significant association between fatigue and having received bone marrow stem cells, having elevated markers of generalized inflammation (erythrocyte sedimentation rate and C-reactive protein), thyroid dysfunction (thyroid-stimulating hormone) and malnutrition (as measured by the nutrition global assessment). The only parameter reflecting cGvHD severity that showed a trend toward association with fatigue was the number of prior cGvHD therapies. NIH cGvHD severity score, number of involved organs, type of onset, intensity of current immunosuppression and current cGvHD activity had no association. Two measures of functional capacity were associated with fatigue (walk velocity and HAP); however, there was no association between fatigue and impairments in range of motion or grip strength. There was also no association between left ventricular dysfunction and fatigue.
Confirming the deleterious effects of fatigue in patients with cGvHD, fatigued respondents had SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) mean scores that were nearly 10 points lower than their counterparts Abbreviations: BSA = body surface area; cGvHD = chronic GvHD; CML = chronic myeloid leukemia; CRP = C-reactive protein; ESA = erythrocyte sedimentation rate; FEV-1 = forced expiratory volume in 1 s; HAP AAS = human activity profile adjusted activity score; HAP MAS = human activity profile maximum activity score; LSS = lee cGvHD symptom scale; MCS = mental component summary score; MDS = myelodysplastic syndrome; MPD = myeloproliferative disorder; NHL = non-Hodgkin's lymphoma; PCS = physical component summary score; SF-36 = short form-36; TSH = thyroid-stimulating hormone. NIH average score = total National Institutes of Health score for each organ system divided by total number of organ systems analyzed (8 for female and 7 for male). Therapeutic intent: active = systemic therapy increased because of worsening disease or substituted or withdrawn owing to lack of response; nonactive = systemic therapy decreased because of improvement or not changed owing to stable disease; indeterminate = not receiving systemic therapy or did not meet previously mentioned criteria. LSS modified = lee cGvHD symptom scale total score without score from 'bothered by loss of energy' item. Lower quartiles indicate preserved function relative to normative values. c TSH was above normal in 9.7% of fatigued patients compared with 6.9% of nonfatigued patients. Bold values indicate statistically significant at P o0.05.
Fatigue in chronic GvHD
A Im et al who were not classified as fatigued. As shown in Table 1 and Figure 1 , fatigued respondents had PCS and MCS median scores that were 1 s.d. lower than those who were not fatigued. The median PCS score for fatigued respondents was 28.6, nearly 22 points below the US population normative value, and indicative of a clinically significant impairment in physical functioning.
Although there was no association between fatigue and measures of cGvHD severity, a number of cGvHD symptoms were associated with fatigue (P o0.005), including sores on the skin, itching, difficulty seeing clearly, frequent cough, colored sputum, shortness of breath with exercise, shortness of breath at rest, need to use oxygen, vomiting, joint and muscle aches, limited joint movement, muscle cramps, weak muscles, need to sleep more/take more naps, fevers, depression, anxiety and difficulty in sleeping (Table 2) .
For the multivariable analysis, to reduce colinearity among the breathing symptoms and among the muscle/joint symptoms, we created two subscale scores by calculating a mean score for each of these symptom groups. The other associated symptoms were entered into the logistic regression model as individual variables. Two symptom items were excluded from further analysis. 'Fevers' was excluded because of the low numbers of patients who reported this symptom, and 'need to sleep more/take naps' was excluded as this item was conceptualized as a behavioral feature of the fatigue experience. Table 3 presents the results of the multivariable logistic regression modeling. After adjusting for age, gender and the number of prior therapies for cGvHD, three factors were independently associated with fatigue in multivariable models: being physically inactive, as reflected by low HAP MAS scores, and experiencing symptom bother because of pulmonary symptoms or muscle/joint symptoms. Considering only these three significant factors, this model correctly identified 66.2% of respondents without fatigue and 72.8% of respondents with fatigue. Other univariate predictors did not reach statistical significance in the multivariable analysis.
DISCUSSION
This study provides several important insights into the experience of fatigue in HCT survivors affected with moderate to severe Abbreviations: HAP MAS = human activity profile maximum activity score; LSS = lee chronic GvHD symptom scale.
a Controlling for stem cell source, donor source, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), thyroid-stimulating hormone (TSH), hemoglobin, the National Institutes of Health (NIH) global severity, 2 min walk velocity, grip strength, body mass index (BMI), nutrition score and univariate significant single item scores from the LSS (anxiety, depression, skin sores, itching, difficulty seeing clearly, vomiting, insomnia). cGvHD. First, fatigue is highly prevalent, with 84% of this sample endorsing any degree of fatigue and ∼ 40% reporting fatigue that was quite or extremely bothersome. This is consistent with prior studies where fatigue was reported more commonly in HCT patients with cGvHD than those without. 26, 50 Second, the consequences of fatigue for physical and mental health are devastating. Fatigued respondents had a median SF-36 PCS score of 28.6 and a median MCS score of 43.6, scores that are markedly lower than the US normative value of 50, and statistically significantly lower than the scores of participants who were not fatigued. 42, 43, 51 Third, we observed few significant associations between demographic, transplant, laboratory or cGvHD disease severity characteristics and fatigue. In contrast, cGvHD symptom bother because of pulmonary symptoms and muscle/joint symptoms, and physical inactivity, were independently associated with fatigue in covariate-adjusted models. Taken together, these findings underscore the importance of routine screening for fatigue in survivors of HCT with cGvHD, and guide future research aimed at identifying the underlying mechanisms of fatigue in this patient population or testing interventions that have been shown in other settings to ameliorate its deleterious effects. 52 Notably, none of the cGvHD clinical characteristics reflecting disease severity (except the number of prior cGvHD therapies) was associated with fatigue in univariate analysis. In multivariable analysis, inactivity and symptom bother because of breathing symptoms and muscle/joint symptoms were significantly associated with being fatigued. Though prior research has not addressed fatigue specifically in cGvHD patient populations, Gielissen et al. 15 examined fatigue in HCT survivors and noted that almost one-third of their respondents were fatigued. The presence of comorbidities was the only factor found to be significantly associated with fatigue; underlying diagnosis, time since transplantation, acute GvHD, duration of hospitalization, medication use, hemoglobin and body mass index were not associated with fatigue. Although the study of Gielissen et al. 15 specifically excluded transplant survivors with severe cGvHD, in our study we similarly found that time since transplant, GvHD severity, hemoglobin and body mass index were not associated with fatigue. In contrast to Gielissen et al., 15 we did not observe an association between fatigue and mood symptoms, including anxiety and depression. In addition, despite the association between fatigue and difficulty in sleeping in the univariate analysis, in the covariate-adjusted models, no statistically significant relationship between fatigue and sleep disturbance (as measured by the single item asking about difficulty sleeping) was observed. An association between fatigue and mood disturbance has been established in other cancer subpopulations. 53 Other investigators have also identified reciprocal relationships among mood disturbance, sleep and fatigue in allogeneic HCT survivors. 54, 55 Although parsing fatigue from depression is challenging, 56 the use of single item measures of anxiety, depression and sleep may have reduced our power to identify associations among these symptoms. Additional exploration of the relationships between fatigue and disturbances in sleep and mood in transplant survivors with cGvHD appears warranted.
The limited association between cGvHD severity measures and fatigue in both the univariate analysis and the multivariate analysis was intriguing. This suggests the need for dedicated study of fatigue in patients with cGvHD, and there are some explanations for this observation that could be addressed in future work. First, we used a single item measure of fatigue, and it may be that a multidimensional measure would have revealed a stronger association. Second, current measures of cGvHD severity may not be able to distinguish active disease from residual damage. Finally, it is unclear whether fatigue in the setting of cGvHD represents a disease feature or whether it reflects a persistent late effect of prior chemoradiotherapy or a manifestation of a comorbidity (for example, congestive heart failure, anemia, sedative effects of medications). Future studies of the phenomenon of fatigue in this patient population should include measures of comorbidity and concurrent medications, as well as putative biomarkers of fatigue 57 and of GvHD, 58 as it is possible that these factors are more influential than are disease severity measures in accounting for fatigue in this population.
Several caveats should be considered in interpreting these findings. Although the cross-sectional study design was an effective way to study a large number of patients, it did not allow for longitudinal assessment to permit causal reasoning about the factors found to be associated with fatigue. Future studies employing a longitudinal design and a comparison group of HCT survivors without cGvHD are warranted to distinguish cGvHD-specific risk factors. Participants in this study also tended to have more severe and steroid-refractory cGvHD, and thus the findings may not fully generalize to patients less severely affected. In addition, it is possible that variables not measured in this study, including comorbidities, concurrent medications and cognitive dysfunction, may be relevant contributors to fatigue. Moreover, it is known that patients may have fatigue before HCT; 59 however, as this was a study of fatigue in long-term transplant survivors, the possible contribution of prior therapies to the fatigue experience could not be determined. Finally, although there is evidence to support the validity of single item measures of fatigue, 60 ,61 a small number of study participants could have been misclassified. This possibility notwithstanding, the significant difference in SF-36 vitality subscale scores between the two groups supports the classification in this study.
Results presented here have several implications for the study of fatigue in patients with cGvHD and the development of clinical interventions. Clinically significant fatigue is highly prevalent and is associated with impairments in health and functioning. These results highlight the importance of fatigue as a symptomatic late effect in HCT survivors with cGvHD. Fatigue is not associated with accepted measures of cGvHD disease severity, perhaps because measure of disease severity may not precisely distinguish cGvHD disease activity from residual tissue damage. Our observations suggest that fatigue in this patient population may have a complex pathogenesis, and that cGvHD symptom burden is a contributor. The finding that cGvHD symptoms and lower levels of physical activity are independently associated with fatigue suggests modifiable potential targets for clinical and behavioral interventions to ameliorate this disabling symptom in survivors of HCT.
